other material
confidence high
sentiment positive
materiality 0.85
Kezar Life Sciences reports positive MISSION Phase 2 results: 64.7% ORR at Week 25, increases to 94.1% in follow-up
Kezar Life Sciences, Inc.
- ORR (≥50% proteinuria reduction) in 11/17 patients (64.7%) at Week 25; increased to 94.1% at Week 29 and 88.2% at Week 37.
- CRR (UPCR ≤0.5) achieved in 35.3% at end of treatment, rising to 41.2% during safety follow-up (Week 29 & 37).
- Mean background corticosteroid use reduced by 53%; by Week 13, 82.4% on ≤10 mg/day steroids.
- SLEDAI-2K reduced from 11.3 baseline to 6.5 at EOT; Physician Global Assessment from 57.2 to 23.9.
- Zetomipzomib well-tolerated; no Grade 3 infections; early terminations in 4/21 patients.